Current snakebite envenoming treatment options consist of animal-derived antisera and are associated with severe adverse reactions due to the heterologous nature of the animal-derived antibodies present in these antisera, and the presence of therapeutically irrelevant antibodies. The African spitting cobras are among the most medically important snakes in sub-Saharan regions due to the severity of the clinical outcomes caused by their cytotoxic venom, which is derived from cytotoxins of the 3FTx toxin family and PLA2. Here we report the results of our progress in identifying human antibodies targeting relevant toxins from the venom of the black necked spitting cobra (Naja nigricolis).
|Number of pages||1|
|Publication status||Published - 2016|
|Event||Symposium for Biological and Life Science Students (SymBLS) 2016 - Cambridge, United Kingdom|
Duration: 25 Nov 2016 → 25 Nov 2016
|Conference||Symposium for Biological and Life Science Students (SymBLS) 2016|
|Period||25/11/2016 → 25/11/2016|